Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors

FDA Drug Safety Communication Peters, 2015, Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition, Diabetes Care, 38, 1687, 10.2337/dc15-0843 Ogawa, 2016, Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors, J Diabetes Investig, 7, 135, 10.1111/jdi.12401 Thawabi, 2015, Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis, N Am J Med Sci, 7, 291, 10.4103/1947-2714.157490 Graham, 2008, Euglycaemic diabetic ketoacidosis, Pract Diab Int, 25, 106, 10.1002/pdi.1220 Prater, 2015, Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes, AACE Clin Case Rep, 1, 1 Erondu, 2015, Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program, Diabetes Care, 38, 1680, 10.2337/dc15-1251 Lamos, 2014, Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes, Expert Opin Investig Drugs, 23, 875, 10.1517/13543784.2014.909407 Perkins, 2014, Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial: Figure 1, Diabetes Care, 37, 1480, 10.2337/dc13-2338 Taylor, 2015, SGLT2 inhibitors may predispose to ketoacidosis, J Clin Endocrinol Metab, 100, 2849, 10.1210/jc.2015-1884 Sha, 2011, Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects, Diabetes Obes Metab, 13, 669, 10.1111/j.1463-1326.2011.01406.x Ferrannini, 2013, Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes, Diabetes Care, 36, 1260, 10.2337/dc12-1503 Ferrannini, 2014, Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients, J Clin Invest, 124, 499, 10.1172/JCI72227 Bonner, 2015, Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion, Nat Med, 21, 512, 10.1038/nm.3828 Rosenstock, 2015, Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors, Diabetes Care, 38, 1638, 10.2337/dc15-1380